Beta Blocker News and Research

RSS

Beta-adrenergic receptor blocking agents (beta-blockers) are drugs with multiple actions on the heart. Blockade of beta-1 receptors results in slowing of heart rate, reduction in myocardial contractility, and lowering of systemic blood pressure. In the context of acute myocardial infarction (AMI), which represents a state of reduced oxygen supply to the affected portion of the heart, these effects may be beneficial as they result in reduced myocardial workload and oxygen demand. Furthermore, beta-blockers may reduce the risk of ventricular arrhythmias, which are an important cause of death following AMI.

New research identifies stress response as trigger for heart inflammation

After a heart attack, the body rapidly floods the injured heart with neutrophils - white blood cells that help repair damage but can also make it worse when too many arrive too quickly.

4 May 2026

Scientists reveal how light-activated drugs change receptor activity

Rendering a drug effective or ineffective in a flash at the appropriate location – this is the focus of research in photopharmacology.

19 Mar 2026

Single daily polypill improves heart function and quality of life in heart failure patients

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, better quality of life, fewer hospitalizations and greater medication adherence than those taking the medications individually, according to a late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

Beta-blockers offer no clinical benefit for myocardial infarction survivors with preserved cardiac function

A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors with preserved cardiac function enrolled in five global clinical trials.

10 Nov 2025

$Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction$

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of patients with MI and mildly reduced left ventricular ejection fraction (LVEF), according to an individual patient data meta-analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Chinese scientists develop highly efficient process for beta-blocker production

Chinese scientists have developed a breakthrough process that significantly improves the efficiency and environmental friendliness of beta-blocker production-with a focus on the widely used compound propranolol, which plays a vital role in managing cardiovascular conditions such as hypertension, arrhythmia, and angina.

20 Jun 2025

Smartwatch alerts retired nurse to heart injury, prompting life-saving hospital care

A smartwatch detected abnormal ECG changes in a 76-year-old woman experiencing chest pain following emotional stress. Hospital investigations confirmed takotsubo (stress) cardiomyopathy, highlighting the potential and limitations of wearable health technology in acute cardiac care.

10 Jun 2025

FAME-3 study reveals similar outcomes for CABG and PCI in severe triple-vessel heart disease

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they underwent open-heart bypass surgery (CABG) or a less invasive procedure called PCI (percutaneous coronary intervention) at five years of follow-up, according to research presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

Discontinuing heart failure medications increases risk of heart-related death

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart failure medications.

17 Mar 2025

Ancient drug could save NHS millions each year when treating older patients with heart conditions

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.

31 Jan 2025

Aircraft noise pollution harms arteries, but heart drugs show promise in animal model research

Alpha- and beta-blockers reduce oxidative stress and inflammation caused by aircraft noise but fail to prevent hypertension, highlighting their potential to protect vascular health in noise-exposed individuals.

9 Jan 2025

Propranolol helps control Parkinson's tremors

The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations.

23 Dec 2024

Higher cardiorespiratory fitness improves cognitive function in older age

Higher cardiorespiratory fitness in older age is linked to the preservation of several core aspects of cognitive ability that are vulnerable to age-related decline, finds research published online in the British Journal of Sports Medicine.

11 Dec 2024

Heart medication may slow the progression of Huntington's disease

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, suggesting new management approaches.

4 Dec 2024

Beta-blocker drugs may slow Huntington's disease progression

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers.

2 Dec 2024

Study suggests beta-blockers may elevate depression symptoms in post-MI patients

In MI patients with preserved heart function, beta-blockers are linked to higher depressive symptoms, indicating a need for careful mental health assessment.

13 Nov 2024

Interrupting beta-blockers after myocardial infarction shows no advantage

The cardiovascular safety of interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the patients' quality of life, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Beta Blocker News and Research

Further Reading

New research identifies stress response as trigger for heart inflammation

Scientists reveal how light-activated drugs change receptor activity

Single daily polypill improves heart function and quality of life in heart failure patients

Beta-blockers offer no clinical benefit for myocardial infarction survivors with preserved cardiac function

Beta blockers reduce mortality and heart failure in MI patients with mildly reduced ejection fraction

Chinese scientists develop highly efficient process for beta-blocker production

Smartwatch alerts retired nurse to heart injury, prompting life-saving hospital care

FAME-3 study reveals similar outcomes for CABG and PCI in severe triple-vessel heart disease

Discontinuing heart failure medications increases risk of heart-related death

Ancient drug could save NHS millions each year when treating older patients with heart conditions

Aircraft noise pollution harms arteries, but heart drugs show promise in animal model research

Propranolol helps control Parkinson's tremors

Higher cardiorespiratory fitness improves cognitive function in older age

Heart medication may slow the progression of Huntington's disease

Beta-blocker drugs may slow Huntington's disease progression

Study suggests beta-blockers may elevate depression symptoms in post-MI patients

Interrupting beta-blockers after myocardial infarction shows no advantage

Gut microbiome discovery paves the way for new heart failure treatments

Amsterdam UMC to lead European consortium in search of solutions to stress among surgical team

Energy drink intake linked to sudden cardiac events in patients with heart genetic disorders

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News